A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

About the trial

Sponsor

AbbVie

Tested

Navitoclax (drug), Ruxolitinib (drug), Celecoxib (drug)

Dates

Started 2019-11-08; completion 2026-12-31

Results posted

Not yet

There are 5 parts to this study for which the primary objectives are to evaluate safety, tolerability, and pharmacokinetics (PK) of navitoclax when administered alone (Part 1) or when administered in combination with ruxolitinib (Part 2). In Part 2, participants must have been receiving a stable dose of ruxolitinib therapy for at least 12 weeks prior to study enrollment. In Part 3, all eligible participants will receive navitoclax, with the primary objective being to evaluate potential navitoclax effect on QTc prolongation. In Part 4, effect of navitoclax is evaluated on the PK, safety, and tolerability of a single dose of celecoxib. In Part 5, all eligible participants will receive ruxol…

From ClinicalTrials.gov, last updated 2025-02-14. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $90,392 in research payments for this study in 2025 (19 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.